Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome
Year: 2018
Type: review
Abstract: The development of new knowledge around the genetic determinants of variable drug action has naturally raised the question of how this new knowledge can be used to improve the outcome of drug therapy. Two broad approaches have been taken: a point-of-care approach in which genotyping for specific variant(s) is undertaken at the time of drug prescription, and a preemptive approach in which multiple genetic variants are typed in an individual patient and the information archived for later use when a drug with a "pharmacogenetic story" is prescribed. This review addresses the current state of implementation, the rationale for these approaches, and barriers that must be overcome. Benefits to pharmacogenetic testing are only now being defined and will be discussed.
DOI: 10.1002/cpt.1035
Institution: Vanderbilt University Medical Center
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Awards: eMERGE Coordinating Center, Integrated, Individualized, Intelligent Prescribing (I3P), Improving Prediction of Drug Action, The Electronic Medical Records and Genomics (eMERGE) Network Phase III - Coordinating Center (U01), VGER, the Vanderbilt Genome-Electronic Records Project, Delineating epidemiological and genetic factors associated with cardiac diastolic dysfunction, G7054413240
OpenAlex ID: W2792968757